 SYDNEY, AUSTRALIA, March 18, 2022 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMOs Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022. 